Pureos Bioventures and Novo Holdings led a $17m round in Engimmune Therapeutics.

Pureos Bioventures and Novo Holdings, venture capital firms, led a $17m round in Engimmune Therapeutics, a platform company that engineers therapies for cancer treatment, with participation from BaseLaunch. “We are very excited to welcome Pureos Bioventures and Novo Holdings to Engimmune, as well as Dr Bent Jakobsen to the Board with his unique track record in TCR therapeutics. The longstanding support from BaseLaunch together with these industry-leading investors and the in-depth expertise of Bent gives Engimmune the standing to become a leading contributor to this competitive yet promising space. Engimmune, with our groundbreaking technology platforms, is well-positioned to develop next-generation TCR therapeutics that are poised to become future breakthrough cancer treatments," Søren Mouritsen, Engimmune CEO.